Currently Enrolling Trials
Juvisync is a single tablet combination of the glucose-lowering medication sitagliptin, the active component of Januvia, with the cholesterol-lowering medication simvastatin, the active component of Zocor.
Juvisync is specifically indicated for the treatment of type II diabetes in patients for whom treatment with both sitagliptin and simvastatin is appropriate.
Juvisync is supplied as a tablet for oral administration. The recommended initial dose is 100 mg/40 mg per day. For patients already taking simvastatin (10, 20, or 40 mg daily) with or without sitagliptin 100 mg daily, Juvisync may be initiated at the dose of 100 mg sitagliptin and the dose of simvastatin already being taken.
The FDA approval of Juvisync was based upon clinical bioequivalence studies in healthy subjects that demonstrated administration of Juvisync is equivalent to co-administration of corresponding doses of the two individual medications, sitagliptin and simvastatin, as separate tablets.
Adverse events associated with the use of simvastatin may include, but are not limited to, the following:
- upper respiratory infection
- abdominal pain
Adverse events associated with the use of sitagliptin may include, but are not limited to, the following:
- upper respiratory tract infection
Mechanism of Action
Juvisync is a single tablet combination of sitagliptin and simvastatin. Sitagliptin is a DPP-4 inhibitor and exerts a glucose-lowering effect. Simvastatin is a specific inhibitor of HMG-CoA reductase and exerts a cholesterol-lowering effect.
For additional information regarding Juvisync or type II diabetes, please visit the Juvisync web page.